Admissions:
None.
Delistings:
None.
Potential** Initial Public Offerings:
17th March: MHA, a professional services provider of audit and assurance, tax, accountancy, and advisory services and independent UK member of Baker Tilly International, announced its Intention to Float on the AIM Market. Up to £101.8 million to be raised, comprising a placing of £95.8 million as well as a retail offer of up to approximately £6 million new Ordinary Shares, raising new capital for the company as well as enabling a sell down by certain partners. Anticipated market capitalisation on admission at the placing price (excluding any take up in the Retail Offer) will be £269m. Expected Admission date is 15th April.
18th March: Uranium Energy Exploration, to be renamed The Smarter Web Company (AQSE:SWC) is a UK-based web design agency, specialising in creating bespoke, mobile-friendly websites and offers a range of online marketing strategies to help businesses enhance their online presence. Services include various web design packages, logo design, Search Engine Optimisation, animation and custom development. It is looking to do a fundraise of £2m on AQSE. Admission expected on or around 22nd April.
Ananda Pharma 0.45p £19.4m (AQSE:ANA)
The UK-based biopharmaceutical Company developing regulatory approved, cannabinoid medicines to treat complex, chronic conditions, announced that trading in the Company's ordinary shares on the OTCQB Venture Market in the US will commence today. There is no associated capital raise with this cross trade and the Ordinary Shares will continue to trade on the Company's primary listing market, the Apex segment of the Aquis Stock Exchange. Cross trading on OTCQB allows the Company to access one of the world's largest investment markets to expand its reach into a broader pool of investors and build brand awareness in the most important pharmaceutical market in the world.
Concurrent Technologies 156.5p £134m (CNC.L)
The designer and manufacturer of leading-edge computer products, systems, and mission-critical solutions used in high-performance markets announces its audited final results for the year ended 31 December 2024. The Company reported record financial performance in FY24, delivering revenue of £40.3m, up 27% on the prior year and Profit before tax increased by c.40% to £5.2m, including a significant investment of £1.1m in the Systems business, as planned. EBITDA increased by 30% to £7.8m (FY23 £6.0m) with closing net cash balances of £13.7m (FY23 £11.1m). The Board will propose, at the Company's AGM to be held on 12 June 2025, a final dividend of 1.1 pence per Ordinary Share in the Company (FY23 1.0p). The Board also expects trading for the full year to be in line with market expectations.
Cyanconnode Holdings 13p £45.2m (CYAN.L)
The global provider of narrowband Radio Frequency (RF) smart mesh networks announces its Indian subsidiary, DigiSmart Networks PVT, has been issued a Letter of Intent for a total contract worth approximately £70m from the Government of Goa's Electricity Department to deploy approximately 750,000 smart meters. This follows the June 2023 report of its empanelment as an Advanced Metering Infrastructure Service Provider (AMISP) so it could bid for and lead smart metering projects in India. DigiSmart is the lead consortium member responsible for installing the meters, communications (RF and cellular), cloud services and meter data management systems. The contract is expected to begin in the next few months and for 27 months thereafter.
Directa Plus 7.25p £7.6m (DCTA.L)
The producer and supplier of graphene-based products for use in consumer and industrial markets announces that Setcar, the Group's environmental subsidiary, has signed a EUR1.59m contract extension agreement with OMV Petrom, for the use of Directa Plus's patented Grafysorber technology to treat oil sludges, emulsions, and contaminated water. This contract extends the original framework agreement, which commenced in 2021, and has generated over EUR1.0m in revenues to date. The contract runs to 31 December 2026, ensuring the continuity of services without interruption.
Distil 0.085p £1.2m (DIS.L)
The owner of premium drinks brands including RedLeg Spiced Rum, Blackwoods Gin and Vodka, and Blavod Black Vodka, announced that it has agreed a new partnership with a U.S. distributor to bring Blavod Black Vodka back into the U.S. market. The partnership with AIKO Importers, Inc. - a nationally recognised importer and brand builder of premium wine and spirits - marks a significant step in the North American relaunch of Blavod. Leveraging AIKO's extensive distribution network of 185 partners across the U.S., Canada and Puerto Rico, as well as strong retail relationships with major accounts like Costco, Total Wine, and Spec's, Blavod will benefit from immediate national reach.
European Green Transition 7.5p £10.8m (EGT.L)
The Company developing green economy assets in Europe announced the appointment of Cathal Friel, the Company's co-founder, as non-executive Chairman with immediate effect. Cathal co-founded EGT in 2021, listed it on AIM in April 2024, and he is its largest shareholder. Daniel Akselson will remain on the Board as a non-executive Director, head of the Audit Committee and will continue to support EGT's strategy to monetise its exploration projects, specifically the Olserum Rare Earth project in Sweden.
Genflow Biosciences 1.15p £4.02m (GENF.L)
The Company focused on developing innovative biological interventions aimed at tackling the effects of aging announced that it has entered into a strategic partnership with Heureka Labs, Inc., a U.S.-based AI-driven discovery and analytics platform. A Master Services Agreement (MSA) was signed by both parties on 11 April 2025, establishing a framework for long-term collaboration. Under the terms of the MSA, Heureka Labs, a technology spin-off from Duke University, will provide Genflow with access to its proprietary AI platform, which specialises in the analysis of high-dimensional genomic data including RNA sequencing and gene expression profiles. The application of Heureka's AI technology is expected to enhance Genflow's ability to interpret complex biological datasets, enabling deeper insights into gene regulatory networks and systemic biological responses.
Scancell Holdings 10p £103.7m (SCLP.L)
The developer of novel immunotherapy products for the treatment of multiple cancers announces a partnership with the NHS Cancer Vaccine Launch Pad (CVLP) to fast-track access for NHS patients into the fourth cohort of the Company's Phase 2 clinical SCOPE study. This cohort will evaluate intradermal administration of Scancell's iSCIB1, potent, targeted "off-the-shelf" Immunobody second generation DNA cancer vaccine, in patients with advanced unresectable melanoma receiving standard of care immunotherapy treatments.
SpaceandPeople 101p £1.90m (SAL.L)
The Company engaged in marketing and selling promotional and retail licensing space on behalf of shopping centers announced its final results for the year ended 31 December 2024. Revenue increased by 15% to £6.7m (2023: £5.8m) and operating profit was up 33% to £0.3m (2023: profit of £0.2m). Cash at the year-end was £1.9m (2023: £1.9m) after a further reduction in debt of £322k; net cash was up 46% to £1.04m (2023: £0.71m). Operational highlights include a new five-year Network Rail contract win and a retail contract with ECE, Germany's largest shopping centre owner and manager, which was extended for a further 5 years.
Zenova Group 0.21p £0.5m (ZED.L)
The innovator in fire suppression and temperature management solutions announced the formation of a joint venture with its local sub-distributor, AED Sh.p.K, to establish a new manufacturing facility in Albania. This strategic initiative is designed to support accelerating demand for Zenova's product suite in Albania and surrounding markets, following strong initial sales delivered by AED. Zenova expects that this manufacturing facility will be fully operational by the middle of May servicing demand AED has developed in the region, and thus the joint venture is projected to generate revenues exceeding EUR2m in the first 12 months. This early demand is expected to be supported by a strong and expanding pipeline of opportunities across key sectors including construction, infrastructure, and government.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
